ASH 2024: Autolus CEO Christian Itin talks about the approval of of the CAR-T Aucatzyl, as well as the company's development pipeline (including autoimmune)
He discusses Autolus' 'fast off' approach to CAR-T and why he believes the safety benefits led to no REMS requirement for Aucatzyl. Plus, ASH presentations, and how Autolus is the only company using a commercially approved CD19 construct in clinical trials for autoimmune disease.